Moderna stock rose 12% due to positive results from seasonal flu vaccine trial.

Moderna (NASDAQ: MRNA) saw a 12% increase in its stock price after releasing positive results from a late-stage trial of its seasonal flu vaccine, mRNA-1010. The vaccine showed a stronger immune response compared to standard flu jabs on the market. This news comes after Moderna withdrew its FDA application for a combination COVID-19/flu vaccine in May. The company plans to resubmit the application alongside the flu vaccine data. While this is a positive development, it may not significantly impact Moderna’s stock in the long run. Investors are advised to consider other potential opportunities before investing in Moderna.

Read more at Nasdaq: Why Moderna Stock Was So Healthy This Week